Article Type
Review
Published
This article examines omecamtiv mecarbil, which is a first-in-class cardiac myosin activator used in the treatment of heart failure.
Review
This article examines omecamtiv mecarbil, which is a first-in-class cardiac myosin activator used in the treatment of heart failure.
Review
This paper summarizes the results from the ground-breaking EMPA-REG OUTCOME study and discusses their significance and clinical implications.